Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma—when, why and where. Leuk Lymphoma. 2018;59:1772–84.

Article  PubMed  Google Scholar 

Derman BA, Fonseca R. Measurable residual disease and decision-making in multiple myeloma. Hematol Oncol Clin N Am. 2024. https://doi.org/10.1016/j.hoc.2023.12.009.

Article  Google Scholar 

Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1:728–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adaptive Biotechnologies Corporation. clonoSEQ assay technical information. https://www.clonoseq.com/sites/default/files/clonoSEQ_TechnicalInformationSummary_21Sept2018.pdf. Accessed 10 Feb 2020.

Hussaini MO, Srivastava J, Lee LW, Nishihori T, Shah BD, Alsina M, et al. Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies. Arch Pathol Lab Med. 2022;146:485–93.

Article  CAS  PubMed  Google Scholar 

Oliva S, Genuardi E, Paris L, D’Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 2023;60: 102016.

Article  PubMed  PubMed Central  Google Scholar 

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2911–8.

Article  CAS  Google Scholar 

Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D’Agostino M et al. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. eClinicalMedicine. 2023. https://doi.org/10.1016/j.eclinm.2023.102017.

Kraeber-Bodéré F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, et al. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Haematologica. 2023;108:621–6.

Article  PubMed  Google Scholar 

Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, González Vélez M, Kosiorek HE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13:1–9.

Google Scholar 

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325–30.

Article  CAS  PubMed  Google Scholar 

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–7.

Article  PubMed  PubMed Central  Google Scholar 

Richard S, Lancman G, Rossi A, Chari A, Parekh S, Sanchez L, et al. Extramedullary relapse post CAR-T. Blood. 2022;140:4301–2.

Article  Google Scholar 

Dima D, Abdallah A-O, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:1–9.

Article  Google Scholar 

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345–50.

Article  CAS  PubMed  Google Scholar 

Keaveney S, Dragan A, Rata M, Blackledge M, Scurr E, Winfield JM, et al. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study. Insights Imaging. 2023;14:170.

Article  PubMed  PubMed Central  Google Scholar 

Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. 2019;291:5–13.

Article  PubMed  Google Scholar 

Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5:479–92.

CAS  PubMed  PubMed Central  Google Scholar 

Kaiser MF, Porta N, Sharma B, Levine D, Koh D-M, Boyd K, et al. Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: results of the iTIMM trial. J Clin Oncol. 2021;39:8012–8012.

Article  Google Scholar 

Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8: 117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcés J-J, Cedena M-T, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:3151–61.

Article  Google Scholar 

Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma. J Clin Oncol. 2023;41:1383–92.

Article  CAS  PubMed  Google Scholar 

Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Morè S, Corradini P, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:3120–31.

Article  CAS  Google Scholar 

Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134:2218–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Notarfranchi L, Zherniakova A, Lasa M, Puig N, Cedena MT, Martinez-Lopez J, et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022;140:2095–7.

Article  Google Scholar 

Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102:e368–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vij R, Mazumder A, Klinger M, O’Dea D, Paasch J, Martin T, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14:131-139.e1.

Article  PubMed  Google Scholar 

Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien M-L, Leleu X, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018;2:2811–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derman BA, Kubicki T, Simmons H, Afrough A, Zonder JA, Grinblatt DL, et al. Early peripheral blood minimal residual disease status by NGS in patients with newly diagnosed multiple myeloma (MM) on a phase 2 trial receiving elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd). Blood. 2023;142:1982.

Article  Google Scholar 

Thoren KL. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol. 2018;55:41–3.

Article  PubMed  Google Scholar 

Kohlhagen M, Dasari S, Willrich M, Hetrick M, Netzel B, Dispenzieri A, et al. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med (CCLM). 2020. https://doi.org/10.1515/cclm-2020-0581.